Advent Access successfully raised a pre-Series A financing round to advance the development and commercialisation of its patented av-Guardian technology.

PUBLISHED: 24 Jan 2018

Congratulations to SSB Co-Programme Director, Ruey on securing pre-Series A financing for his own startup, Advent Access. 

Advent Access Pte Ltd is a Singapore-based medical device startup in clinicals stage. Founded based on Stanford Biodesign principles, the company’s mission is to pioneer innovations that preserve fistula access, reduce dialysis cost and restore quality of life for kidney failure patients in Asia and across the world. Advent Access has innovated a proprietary “device-guided blunt access” platform that aims to preserve the health of an AV fistula vessel; and scale hemodialysis centers to treat a larger patient population with less nursing support or remotely at home. The startup's first product is the av-GuardianTM – a subcutaneous access device placed adjacent and non-invasive to an AV fistula. Implantable in a treatment room, the av-GuardianTM is further designed with an ease of use to empower patients independent and less-painful self-cannulation with a blunt needle.

You can view the article here <http://www.straitstimes.com/business/companies-markets/temasek-invests-in-singapore-medtech-firm-advent-access>.